Bacterial Lipopolysaccharides Pretreatment Protects Against Mutagenic and Immunosuppressor Effects of Cyclophosphamide in Mice

The mutagenic and immunosuppressory effects of cyclophosphamide (cyp) are still the primary limitation to wider application for treating a variety of human malignancies. on the one hand, cyp treatment predisposes transplant recipients and cancer patients to risk of bacterial, fungal, and viral infections, in the other word the, lipopolysaccharide (lps), an endotoxin found in cell walls of gram- negative bacteria, has been shown to play a significant role in development a of multiple immune system responses and can cause a fatal pathological effect. the present investigation is focused on immunization of mice with the endotoxin lps prior to cyp treatment, in an attempt to reduce mutagenicity and immunosuppressory effects caused by cyp. the in vivo anti-cytotoxicity and anti- mutagenicity of the inflammatory agents of bacterial lipopolysaccharides (lps) isolated from aeromonas hydrophila was evaluated by bone marrow chromosomal aberrations assay, differential white blood cells (wbcs) count and respiratory burst enzymatic assays for phagocytosis in mice exposed to cyp. the data presented in this article indicates that, treatment with low dose of bacterial lps once a week for four weeks at a dose of 0.2 ml of lps suspension (50 ìg/kg mice/week), was non- cytotoxic and un-mutagenic to the animal cells. however, pretreatment with low dose of bacterial lps significantly increase cellular resistance to the mutagenic and immunosuppressory effects of cyp. in conclusion, this immunization protocol suggests that immunization of mice by lps prior to cyp treatment may induce a number of adaptive antimutagenic and immune response molecular mechanisms.